阿托伐他汀对扩张型心肌病患者内皮功能的影响  

作　　者：谢登荣 杨全坤 刘仁水[1] 罗正平[1] 

机构地区：[1]湖南省怀化市第二人民医院心内科,418000

出　　处：《当代医学》2009年第22期68-69,共2页Contemporary Medicine

摘　　要：目的探讨原发性扩张型心肌病(DCM)患者血管内皮功能状况,以及阿托伐他汀对内皮功能状况的影响。方法67例DCM患者随机给予或不给阿托伐他汀治疗8周后,观察血浆血管性假血友病因子(vwF),肱动脉内径扩张度(FMD)水平的改变。35例健康体检者作为正常对照组。结果两组DCM患者基础vWF水平高于健康对照组(P<0.01),FMD水平低于正常对照组(P<0.01);经过治疗后,阿托伐他汀组比非阿托伐他汀组vwF值降低更明显(P<0.05),FMD值升高但无显著性差异。结论DCM患者存在内皮功能失调,阿托伐他汀能够改善DCM病人内皮功能紊乱。Objective To investigate the Effect of atorvastatin on relationship endothelial function in patients with primary dilated cardfomyopathy（DCM）.Methods 67 patients with DCM and 32 healthy controls were enrolled in this study. The plasma von willebrand factor（vWF） was detected and flow-mediated dilation（FMD）of right brachial artery was measured. Results The baseline value of vWF in patients with DCM was higher than that in healthy control subjects（P〈0.01）, and the baseline values of FMD was lower than that in control（P〈0.01）. At the endpoint of this 8-week study, vWF was significantly decreased while FMD was significantly increased in the treatment groups.Conclusion Endothelial dysfunction exists in DCM patients. Atorvastatin improves the poor vascular endothelial function in these patients, which may play a beneficial role in preventing the deterioration of DCM.

关 键 词：扩张型心肌病 内皮功能紊乱 VWF FMD 

分 类 号：R542.21[医药卫生—心血管疾病]